Repros Therapeutics Inc (RPRX)

[Bio_pete]

Spartex, I've been in AIS since $1.00 and I know RJF had shares at one time. They have three separate un-named commercial deals with TEVA products, one of which should come to market in 2007 for their injection system. I'm expecting this to be pushed back to 2008.

Anturol for overactive bladder has shown positive therapeutic results with reduced adverse events in comparison to oral and patch formulations. They will be initiating 12 week studies this year measuring the number of incontinence episodes. $4 billion urinary incontinence market.

Antares has the rights to the NDA filed for Elestrin and has the rights to market Elestrin in other parts of the world. Elestrin is a 50% lower dosage of currently approved estrogen therapies. Bradley expects to market Elestrin in the U.S. by mid-2007. AIS will receive milestone payments which could amount up to $13 million and royalties upon commercialization.

I wouldn't be surprised to see the shares slide back to the $1.70 area, but the company is a pretty safe play if you want to start taking a position. They have enough cash to fund the operations and management has stated they would be cash flow positive at some point this year. Biggest problem is management salaries and options. There is no near term catalyst unless TEVA makes an announcement. Company is a buy-out target in my opinion.